IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience

Interleukin-17A inhibitors are a promising alternative to tumor necrosis factor-α inhibitors for the treatment of psoriasis. In-class switch has been hardly investigated for interleukin-17A inhibitors. We report the experience (2017-2018) of a tertiary medical center with interleukin-17A-inhibitor s...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Shany Sherman (Autor), Efrat Solomon Cohen (Autor), Iris Amitay-Laish (Autor), Emmilia Hodak (Autor), Lev Pavlovsky (Autor)
Format: Knjiga
Izdano: Medical Journals Sweden, 2019-05-01T00:00:00Z.
Teme:
Online pristup:Connect to this object online.
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Internet

Connect to this object online.

3rd Floor Main Library

Detalji primjeraka od 3rd Floor Main Library
Signatura: A1234.567
Primjerak 1 Dostupno